| Literature DB >> 32215032 |
Qing-Sheng Yu1,2, Zhou Zheng1,2, Hui Peng1,2, Yi Shen1,2, Ju-da Liu1,2, Fu-Hai Zhou1,2.
Abstract
OBJECTIVE: Early nutritional support in patients with gastric cancer can improve their nutritional status, but the impact on immune function has not been confirmed. This study aimed to analyze the effects of Qihuang decoction combined with enteral nutrition on nutrition and the immune function of postoperative gastric cancer.Entities:
Year: 2020 PMID: 32215032 PMCID: PMC7079248 DOI: 10.1155/2020/1795107
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Diagram showing the flow of participants' enrollment.
General information of patients with gastric cancer in the two groups.
| Group | Study group ( | Control group ( |
|
|
|---|---|---|---|---|
|
| ||||
| Male/female | 81/39 | 96/21 | 3.087 | 0.079 |
| Mean age(mean ± SD, years) | 65.33 ± 11.41 | 66.75 ± 9.00 | −1.070 | 0.286 |
|
| ||||
|
| ||||
| Cardiac region | 12 | 10 | ||
| Fundus of stomach | 28 | 25 | 0.936 | 0.817 |
| Gastric body | 38 | 34 | ||
| Antrum of stomach | 42 | 48 | ||
|
| ||||
|
| ||||
| Stage I | 32 | 28 | ||
| Stage II | 42 | 39 | 0.717 | 0.869 |
| Stage III | 36 | 41 | ||
| Stage IV | 10 | 9 | ||
|
| ||||
|
| ||||
| Well | 55 | 44 | ||
| Moderately | 42 | 48 | 1.668 | 0.434 |
| Poorly | 23 | 25 | ||
| Surgical method | ||||
| Distal gastrectomy | 38 | 33 | 0.338 | 0.561 |
| Total gastrectomy | 82 | 84 | ||
| Time of operation(min) | 214.19 ± 8.24 | 213.29 ± 6.09 | 0.959 | 0.338 |
| Intraoperative blood loss(ml) | 220.06 ± 8.75 | 221.09 ± 7.76 | −0.957 | 0.340 |
Comparison of changes in nutritional status.
| Indexs | Study group ( | Control group( |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | Day 1 | Day 3 | Day 7 | Day 14 | Before | Day 1 | Day 3 | Day7 | Day14 | Before | Day 1 | Day 3 | Day7 | Day14 | |
| HB(g/L) | 106.33 ± 7.47 | 98.31 ± 6.92 | 101.24 ± 7.00 | 105.26 ± 6.87#& | 107.26 ± 6.84#&∆ | 106.51 ± 11.14 | 97.52 ± 8.17 | 101.14 ± 15.59 | 104.03 ± 10.19 | 106.19 ± 11.12#&∆ | 0.884 | 0.425 | 0.947 | 0.292 | 0.372 |
| ALB(g/L) | 35.90 ± 4.76 | 30.12 ± 4.55 | 32.14 ± 4.52 | 36.23 ± 4.74#& | 39.34 ± 4.58 | 35.15 ± 3.84 | 30.53 ± 4.73 | 31.45 ± 4.38 | 33.87 ± 3.01 | 35.98 ± 3.61#&∆ | 0.185 | 0.499 | 0.237 | ≤0.001 | ≤0.001 |
| TP(g/L) | 58.23 ± 6.35 | 49.32 ± 5.73 | 52.35 ± 5.72 | 57.60 ± 5.46#& | 62.31 ± 5.26 | 59.41 ± 4.61 | 49.18 ± 6.96 | 51.61 ± 5.14 | 52.88 ± 3.42 | 59.86 ± 5.98#&∆ | 0.103 | 0.872 | 0.301 | ≤0.001 | ≤0.001 |
| PA(mg/L) | 207.10 ± 32.74 | 201.32 ± 31.38 | 208.49 ± 24.79# | 211.28 ± 19.33 | 213.30 ± 31.26 | 206.67 ± 21.30 | 200.97 ± 24.25 | 201.68 ± 14.41 | 205.12 ± 9.69#& | 206.13 ± 12.45#&∆ | 0.775 | 0.925 | 0.011 | 0.002 | 0.022 |
(1) All values are means ± sem. There was no difference between groups before surgery. PN-value: study group compared with the control group. (2) P < 0.05 compared with before surgery; #P < 0.05 compared with Day 1; &P < 0.05 compared with Day 3; ΔP < 0.05 compared with Day 7 (all of them adopt ANOVA and LSD post hoc test) .(3) Normal range of these indexes: hemoglobin (HB): 130∼175 g/L; albumin (ALB): 40–55 g/L; total protein (TP): 60∼80 g/L; prealbumin protein (PA), 100–400 mg/L.
Comparison of immune function.
| Study group ( | Control group ( |
| |
|---|---|---|---|
|
| |||
| Before | 50.11 ± 7.53 | 49.42 ± 5.37 | 0.419 |
| Day 1 | 43.13 ± 7.64 | 42.67 ± 4.07 | 0.567 |
| Day 3 | 47.34 ± 7.59 | 46.06 ± 3.45 | 0.097 |
| Day 7 | 48.12 ± 7.32 | 46.01 ± 7.25 | 0.027 |
| Day 14 | 52.20 ± 7.48 | 48.78 ± 7.06#&∆ | ≤0.001 |
|
| 4.069 |
| 0.008 |
|
| |||
|
| |||
| Before | 29.00 ± 4.73 | 29.49 ± 4.22 | 0.404 |
| Day 1 | 23.33 ± 3.64 | 24.42 ± 5.35 | 0.412 |
| Day 3 | 27.01 ± 4.74 | 26.43 ± 5.24 | 0.370 |
| Day 7 | 31.89 ± 4.09 | 30.05 ± 6.28# | 0.008 |
| Day 14 | 34.00 ± 4.66 | 30.64 ± 5.93 | ≤0.001 |
|
| 9.990 |
| ≤0.001 |
|
| |||
|
| |||
| Before | 0.79 ± 0.45 | 0.88 ± 0.27 | 0.098 |
| Day 1 | 0.70 ± 0.40 | 0.75 ± 0.15 | 0.205 |
| Day 3 | 0.82 ± 0.39# | 0.80 ± 0.35 | 0.731 |
| Day 7 | 0.94 ± 0.38 | 0.84 ± 0.19# | 0.010 |
| Day 14 | 1.43 ± 0.64 | 1.01 ± 0.27 | ≤0.001 |
|
| 48.682 |
| ≤0.001 |
|
| |||
|
| |||
| Before | 1.62 ± 0.38 | 1.59 ± 0.27 | 0.420 |
| Day 1 | 1.32 ± 0.29 | 1.31 ± 0.16 | 0.592 |
| Day 3 | 2.03 ± 0.53 | 1.63 ± 0.36# | ≤0.001 |
| Day 7 | 2.45 ± 0.42 | 1.83 ± 0.19 | ≤0.001 |
| Day 14 | 3.44 ± 0.42 | 2.67 ± 0.21 | ≤0.001 |
|
| 64.849 |
| ≤0.001 |
|
| |||
|
| |||
| Before | 1.72 ± 0.36 | 1.66 ± 0.30 | 0.165 |
| Day 1 | 1.10 ± 0.43 | 1.02 ± 0.25 | 0.079 |
| Day 3 | 1.92 ± 0.39 | 1.30 ± 0.44 | ≤0.001 |
| Day 7 | 2.30 ± 0.36 | 1.42 ± 0.22 | ≤0.001 |
| Day 14 | 2.42 ± 0.41 | 1.90 ± 0.12 | ≤0.001 |
|
| 71.784 |
| ≤0.001 |
|
| |||
|
| |||
| Before | 9.32 ± 3.86 | 9.64 ± 2.23 | 0.442 |
| Day 1 | 6.30 ± 3.53 | 6.02 ± 0.32 | 0.394 |
| Day 3 | 7.12 ± 3.38 | 6.32 ± 1.51 | 0.020 |
| Day 7 | 8.35 ± 1.44 | 7.66 ± 0.40 | ≤0.001 |
| Day 14 | 10.44 ± 3.31 | 8.92 ± 0.95 | ≤0.001 |
|
| 10.257 |
| ≤0.001 |
(1) All values are means ± sem. There was no difference between groups before surgery. (2) P-values for the difference between study group and control group with respect to the time point were calculated as treatment × time interaction. P-values for the difference between study group and control group with all the time points were calculated as treatment × time interaction. (3) P < 0.05 compared with before surgery; #P < 0.05 compared with Day 1; &P < 0.05 compared with Day 3; ΔP < 0.05 compared with Day 7 (all of them adopt ANOVA and LSD post hoc test).
Postoperative complications n (%) in the study group and control group.
| Complication | Study group ( | Control group ( | Total ( |
|
|
|---|---|---|---|---|---|
| Anastomotic leakage | 4 (3.33) | 6 (5.13) | 10 (4.22) | — |
|
| Abdominal hemorrhage | 10 (8.33) | 13 (11.11) | 23 (9.70) | 0.522 |
|
| Abdominal infection | 5 (4.17) | 15 (12.82) | 20 (8.44) | 5.742 |
|
| Pulmonary infection | 12 (10.00) | 23 (19.66) | 35 (14.77) | 4.39 |
|
| Incision infection | 7 (5.83) | 16 (13.68) | 23 (9.70) | 4.157 |
|
| Urinary infection | 5 (4.17) | 18 (15.38) | 15 (6.33) | 8.507 |
|
| Gastroparesis syndrome | 2 (1.67) | 5 (4.27) | 7 (2.95) | — |
|
| Early mortality | 0 (0) | 2 (1.71) | 2 (0.84) | — |
|
(1) Pχ2: in Pearson Chi-square test; P : in Fisher's exact test; n: the number of examined patients. (2) χ2: random variable Chi-square test value.